Individual Patient Compassionate Use of Mirdametinib

ConditionsNeurofibromatosis Type 1-Associated Plexiform Neurofibromas Histiocytic Neoplasm Other MAP-K Pathway Driven Diseases

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

Age2+

SponsorSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

About this trial

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Eligibility criteria

Qualifiers

Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.

Patient does not qualify to participate in an ongoing clinical trial.

Disqualifiers

None

Trial design

Treatments tested in this trial

Mirdametinib (MEK Inhibitor)

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Lead sponsor

Source ClinicalTrials.gov